AXSM Axsome Gross Profit Rate

Official company branding of Axsome Corp (AXSM)

The Axsome Therapeutics (AXSM) R&D center is actively implementing cutting-edge neurological solutions, expanding its pipeline of treatments for narcolepsy and depression. Stable cash flow is secured by patents and patient adherence to CNS therapies. The gross margin clearly illustrates this efficiency, where 92.00 serves as the current metric level. High physician confidence in new drugs is rapidly strengthening the company's market image.

Axsome Corp (AXSM) Gross Profitability: for the period 07/04/2022 - 11/19/2026

Comprehensive metric breakdowns and analytics for Axsome Corp (AXSM)

- stock value and consensus price forecast:
Summary company analysis:Axsome Therapeutics, Inc. - AXSM
Signature product of Axsome Therapeutics Inc

The market views Axsome Therapeutics (AXSM) as a promising asset due to the company's ability to repurpose molecules into unique CNS drugs. An analysis of historical gross margins allows for the measurement of revenue after deducting direct production costs, which, given the inelastic demand for antidepressants, confirms the business's strong pricing power and fundamental stability.

Direct competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Profitability acadia-pharm.com (ACAD)|Gross Margin Xenon Pharmaceuticals (XENE)|Gross Profitability Viking Therapeutics VKTX|Gross Profit Rate SUPN|CPRX - Gross Profitability|Gross Profit Margin Denali Therapeutics|HRMY: Gross Margin|Biohaven - Gross Profit Rate|Return on Gross Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Return on Sales by Gross Profit|Return on Gross Profit PRAX (Praxis Medicines)|Anavex Corp - Gross Return on Sales|Gross Profitability CeriBell CBLL|Return on Sales by Gross Profit Prothena Biosciences (PRTA)|ALEC: Return on Gross Profit|ANNX - Gross Margin|Omeros Corp. (OMER) - Gross Profitability|Gross Profit Margin Neurogene Inc. (NGNE)|Return on Gross Profit ACIU|Gross Profitability VYGR|Gross Profitability Neumora (NMRA)|SCLX - Gross Profit Margin|Gross Margin TVGN (Tevogen Bio Holdings Inc.)|Gross Profit Rate ACOG|Cognition Therapeutics Inc. - Gross Margin|IKT - Gross Margin|SAVA: Gross Margin|Assertio Holdings, Inc. - Gross Profit Rate|COYA (Coya) - Gross Margin|Gross Return on Sales VTGN (Vistagen Therapeutics)|Gross Profitability Ovid Rx (OVID)|Acumen Pharmaceuticals - Gross Return on Sales|Gross Profitability CervoMed, Inc. CRVO|Gross Margin Alterity Therapeutics ATHE|CLNN: Return on Gross Profit|PEPG (pepgen.com) - Gross Return on Sales|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)